494 related articles for article (PubMed ID: 31624029)
21. Outcomes associated with recent guideline recommendations removing metronidazole for treatment of non-severe Clostridioides difficile infection: a retrospective, observational, nationwide cohort study.
Gentry CA; Campbell DL; Williams RJ
Int J Antimicrob Agents; 2021 Mar; 57(3):106282. PubMed ID: 33465458
[TBL] [Abstract][Full Text] [Related]
22. Fidaxomicin versus oral vancomycin for severe Clostridium difficile infection: a retrospective cohort study.
Gentry CA; Nguyen PK; Thind S; Kurdgelashvili G; Skrepnek GH; Williams RJ
Clin Microbiol Infect; 2019 Aug; 25(8):987-993. PubMed ID: 30583055
[TBL] [Abstract][Full Text] [Related]
23. The Trend for Antibiotic Use for Clostridioides (Clostridium) difficile Infection in Japan.
Ishii S; Muraki Y; Kusama Y; Yagi T; Goto R; Ebisui A; Kawabe A; Inose R; Ohmagari N
Biol Pharm Bull; 2020; 43(4):693-696. PubMed ID: 32238711
[TBL] [Abstract][Full Text] [Related]
24. Antibacterial activity of ibezapolstat against antimicrobial-resistant clinical strains of
Bassères E; Eubank TA; Begum K; Alam MJ; Jo J; Le TM; Lancaster CK; Gonzales-Luna AJ; Garey KW
Antimicrob Agents Chemother; 2024 Mar; 68(3):e0162123. PubMed ID: 38364016
[TBL] [Abstract][Full Text] [Related]
25. Cost-effectiveness analysis of initial treatment strategies for mild-to-moderate
Ford DC; Schroeder MC; Ince D; Ernst EJ
Am J Health Syst Pharm; 2018 Aug; 75(15):1110-1121. PubMed ID: 29903711
[TBL] [Abstract][Full Text] [Related]
26. Comparative effectiveness of Clostridium difficile treatments: a systematic review.
Drekonja DM; Butler M; MacDonald R; Bliss D; Filice GA; Rector TS; Wilt TJ
Ann Intern Med; 2011 Dec; 155(12):839-47. PubMed ID: 22184691
[TBL] [Abstract][Full Text] [Related]
27. Microbiome-preserving antibiotics for the treatment of Clostridioides difficile infection: a systematic review and meta-analysis.
Kravets AM; Hanneke R; Nelson RL
Tech Coloproctol; 2023 Dec; 28(1):20. PubMed ID: 38112980
[TBL] [Abstract][Full Text] [Related]
28. Current and emerging management options for Clostridium difficile infection: what is the role of fidaxomicin?
Cornely OA
Clin Microbiol Infect; 2012 Dec; 18 Suppl 6():28-35. PubMed ID: 23121552
[TBL] [Abstract][Full Text] [Related]
29. Fidaxomicin versus vancomycin for Clostridium difficile infection.
Louie TJ; Miller MA; Mullane KM; Weiss K; Lentnek A; Golan Y; Gorbach S; Sears P; Shue YK;
N Engl J Med; 2011 Feb; 364(5):422-31. PubMed ID: 21288078
[TBL] [Abstract][Full Text] [Related]
30. Clostridium difficile infection in older adults: a review and update on its management.
Kee VR
Am J Geriatr Pharmacother; 2012 Feb; 10(1):14-24. PubMed ID: 22260856
[TBL] [Abstract][Full Text] [Related]
31. Fidaxomicin inhibits spore production in Clostridium difficile.
Babakhani F; Bouillaut L; Gomez A; Sears P; Nguyen L; Sonenshein AL
Clin Infect Dis; 2012 Aug; 55 Suppl 2(Suppl 2):S162-9. PubMed ID: 22752866
[TBL] [Abstract][Full Text] [Related]
32. [Antimicrobial therapy of Clostridium difficile infection. Systematic review and meta-analysis of the scientific evidence].
Brodszky V; Gulácsi L; Ludwig E; Prinz G; Banai J; Reményi P; Strbák B; Kertész A; Kopcsóné Németh I; Zsoldiné Urbán E; Baji P; Péntek M
Orv Hetil; 2013 Jun; 154(23):890-9. PubMed ID: 23728312
[TBL] [Abstract][Full Text] [Related]
33. Cost-effectiveness analysis on the use of fidaxomicin and vancomycin to treat Clostridium difficile infection in France.
Watt M; Dinh A; Le Monnier A; Tilleul P
J Med Econ; 2017 Jul; 20(7):678-686. PubMed ID: 28299963
[TBL] [Abstract][Full Text] [Related]
34. Clinical outcomes of fidaxomicin vs oral vancomycin in recurrent Clostridium difficile infection.
Tieu JD; Williams RJ; Skrepnek GH; Gentry CA
J Clin Pharm Ther; 2019 Apr; 44(2):220-228. PubMed ID: 30350418
[TBL] [Abstract][Full Text] [Related]
35. [Individualized treatment strategies for Clostridium difficile infections].
Solbach P; Dersch P; Bachmann O
Internist (Berl); 2017 Jul; 58(7):675-681. PubMed ID: 28589214
[TBL] [Abstract][Full Text] [Related]
36. Therapy for Clostridium difficile infection - any news beyond Metronidazole and Vancomycin?
Manthey CF; Eckmann L; Fuhrmann V
Expert Rev Clin Pharmacol; 2017 Nov; 10(11):1239-1250. PubMed ID: 28766951
[TBL] [Abstract][Full Text] [Related]
37. A network meta-analysis of randomized controlled trials exploring the role of fecal microbiota transplantation in recurrent
Rokkas T; Gisbert JP; Gasbarrini A; Hold GL; Tilg H; Malfertheiner P; Megraud F; O'Morain C
United European Gastroenterol J; 2019 Oct; 7(8):1051-1063. PubMed ID: 31662862
[TBL] [Abstract][Full Text] [Related]
38. Fidaxomicin--the new drug for Clostridium difficile infection.
Vaishnavi C
Indian J Med Res; 2015 Apr; 141(4):398-407. PubMed ID: 26112840
[TBL] [Abstract][Full Text] [Related]
39. Successful treatment of simulated Clostridium difficile infection in a human gut model by fidaxomicin first line and after vancomycin or metronidazole failure.
Chilton CH; Crowther GS; Freeman J; Todhunter SL; Nicholson S; Longshaw CM; Wilcox MH
J Antimicrob Chemother; 2014 Feb; 69(2):451-62. PubMed ID: 24003182
[TBL] [Abstract][Full Text] [Related]
40. Fidaxomicin vs Vancomycin for the Treatment of a First Episode of Clostridium Difficile Infection: A Meta-analysis and Systematic Review.
Al Momani LA; Abughanimeh O; Boonpheng B; Gabriel JG; Young M
Cureus; 2018 Jun; 10(6):e2778. PubMed ID: 30112254
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]